Recursion, Roche, and its Genentech subsidiary have unveiled a whole-genome map of specialized microglial immune cells that they plan to use toward revealing significant new targets in ...

Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Artificial intelligence: where do we begin? Do we start with the data, or do we start by reinventing our processes?

Amid all the change, there remains a constant: the quality of an AI model’s outputs is only ever as good as the data that feeds it. Data management technologies and practices have also been advancing, ...

You’re reading State of Crypto, a CoinDesk newsletter looking at the intersection of cryptocurrency and government. Click here to sign up for future editions. Policy work around digital assets seems ...

AI is transforming learning – not by replacing people, but by empowering learning professionals to blend data, creativity and empathy.